Male fertility in relapsing-remitting multiple sclerosis patients treated with natalizumab and ocrelizumab: A prospective case-control study

被引：10

作者：

D'Amico, Emanuele ^{[1
]}

Zanghi, Aurora ^{[1
]}

Calogero, Aldo Eugenio ^{[2
]}

Patti, Francesco ^{[1
]}

机构：

[1] Univ Catania, Dept Med Surg Sci & Adv Technol GF Ingrassia, Via Santa Sofia 78, I-95123 Catania, Italy

[2] Univ Catania, Dept Clin & Expt Med, Catania, Italy

来源：

MULTIPLE SCLEROSIS JOURNAL | 2021年 / 27卷 / 14期

关键词：

Multiple sclerosis; men fertility; gonadal steroids; ocrelizumab; natalizumab; SEMEN QUALITY; PREGNANCY; WOMEN;

D O I：

10.1177/13524585211009208

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Scarce data are available about the impact of natalizumab (NTZ) and ocrelizumab (OCR) on male fertility in relapsing-remitting multiple sclerosis (RRMS). In this case-control prospective study, the gonadal steroids and the sperm parameters have been analysed at the time of the RRMS diagnosis and after 12 months from the beginning of the investigated therapies. Sixteen men with RRMS and sixteen matched healthy controls were included. At enrolment and after 12 months on therapy, the gonadal steroids and the sperm parameters of men with RRMS did not differ from the healthy controls. In conclusion, therapy with NTZ and OCR had no impact on fertility status in our cohort of men with RRMS. Further randomized and prospective studies are needed.

引用

页码：2284 / 2287

页数：4

共 50 条

[31] Progressive multifocal encephalopathy in the first patient with relapsing-remitting multiple sclerosis treated with ocrelizumab
Puig Casadevall, M.
Alvarez Bravo, G.
Coll-Martinez, C.
Quiroga-Varela, A.
Robles-Cedeno, R.
Gonzalez del Rio, M.
Salavedra-Pont, J.
Miguela, A.
Gich, J.
Ramio-Torrenta, L.
Boix-Lago, A.
Laguillo-Sala, G.
MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 679 - 680
[32] Bruising following natalizumab infusion for relapsing-remitting multiple sclerosis: A case report
Gatzonis S.
Siatouni A.
Journal of Medical Case Reports, 3 (1)
[33] The incidence of infusion associated reactions in Ocrelizumab-treated Relapsing-Remitting Multiple Sclerosis patients.
Bewick, C.
Das, E.
Collins, J.
Nash, C.
Fisniku, L.
EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 684 - 684
[34] Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis
Prosperini, L.
Mancinelli, C. R.
Gianni, C.
Barletta, V.
Fubelli, F.
Borriello, G.
Pozzilli, C.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 469 - 470
[35] Natalizumab: A guide to its use in relapsing-remitting multiple sclerosis
Keating G.M.
McCormack P.L.
Drugs & Therapy Perspectives, 2014, 30 (2) : 48 - 54
[36] Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis
Meuth, Sven G.
Bittner, Stefan
Seiler, Carola
Goebel, Kerstin
Wiendl, Heinz
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 (02) : 198 - 203
[37] The Association of Salivary Cortisol Levels With Depression, Anxiety, and Quality of Life in Male Relapsing-Remitting Multiple Sclerosis Patients: A Case-Control Study
Mokary, Yousef
Vaheb, Saeed
Panah, Mohammad Yazdan
Afshari-Safavi, Alireza
Ghaffary, Elham Moases
Barzegar, Mahdi
Shirbacheh, Ali
Shaygannejad, Vahid
Mirmosayyeb, Omid
ACTA NEUROLOGICA SCANDINAVICA, 2024, 2024
[38] COST-EFFECTIVENESS OF NATALIZUMAB IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN RUSSIA
Matveev, N., V
Sabanov, A., V
Luneva, A., V
VALUE IN HEALTH, 2014, 17 (03) : A60 - A60
[39] Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing-Remitting Multiple Sclerosis
Escribano, Begona M.
Aguilar-Luque, Macarena
Bahamonde, Carmen
Conde, Cristina
Lillo, Rafael
Sanchez-Lopez, Fernando
Giraldo, Ana I.
Cruz, Antonio H.
Luque, Evelio
Gascon, Felix
Aguera, Eduardo
Tunez, Isaac
CURRENT PHARMACEUTICAL DESIGN, 2016, 22 (31) : 4876 - 4880
[40] Natalizumab restores evoked potential abnormalities in patients with relapsing-remitting multiple sclerosis
Bittner, S.
Meuth, S.
Seiler, C.
Reiners, K.
Wiendl, H.
MULTIPLE SCLEROSIS, 2009, 15 (09): : S247 - S247

← 1 2 3 4 5 →